Intellia Therapeutics Statistics Share Statistics Intellia Therapeutics has 107.35M
shares outstanding. The number of shares has increased by 1.97%
in one year.
Shares Outstanding 107.35M Shares Change (YoY) 1.97% Shares Change (QoQ) 0.06% Owned by Institutions (%) 97.83% Shares Floating 101.11M Failed to Deliver (FTD) Shares 29,404 FTD / Avg. Volume 0.63%
Short Selling Information The latest short interest is 27.73M, so 25.83% of the outstanding
shares have been sold short.
Short Interest 27.73M Short % of Shares Out 25.83% Short % of Float 29.26% Short Ratio (days to cover) 5.7
Valuation Ratios The PE ratio is -2.22 and the forward
PE ratio is -2.93.
Intellia Therapeutics's PEG ratio is
0.71.
PE Ratio -2.22 Forward PE -2.93 PS Ratio 19.91 Forward PS 25.1 PB Ratio 1.32 P/FCF Ratio -3.25 PEG Ratio 0.71
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Intellia Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 5.77,
with a Debt / Equity ratio of 0.24.
Current Ratio 5.77 Quick Ratio 5.77 Debt / Equity 0.24 Debt / EBITDA -0.4 Debt / FCF -0.59 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $143.62K Profits Per Employee $-1.29M Employee Count 403 Asset Turnover 0.05 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -48.26% in the
last 52 weeks. The beta is 2.28, so Intellia Therapeutics's
price volatility has been higher than the market average.
Beta 2.28 52-Week Price Change -48.26% 50-Day Moving Average 11.61 200-Day Moving Average 10.34 Relative Strength Index (RSI) 50.54 Average Volume (20 Days) 4,649,395
Income Statement In the last 12 months, Intellia Therapeutics had revenue of 57.88M
and earned -519.02M
in profits. Earnings per share was -5.25.
Revenue 57.88M Gross Profit 47.59M Operating Income -534.26M Net Income -519.02M EBITDA -523.98M EBIT -534.26M Earnings Per Share (EPS) -5.25
Full Income Statement Balance Sheet The company has 189.18M in cash and 210.2M in
debt, giving a net cash position of -21.02M.
Cash & Cash Equivalents 189.18M Total Debt 210.2M Net Cash -21.02M Retained Earnings -2.18B Total Assets 898.89M Working Capital 400.45M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -348.88M
and capital expenditures -5.78M, giving a free cash flow of -354.66M.
Operating Cash Flow -348.88M Capital Expenditures -5.78M Free Cash Flow -354.66M FCF Per Share -3.59
Full Cash Flow Statement Margins Gross margin is 82.23%, with operating and profit margins of -923.1% and -896.77%.
Gross Margin 82.23% Operating Margin -923.1% Pretax Margin -896.77% Profit Margin -896.77% EBITDA Margin -905.33% EBIT Margin -923.1% FCF Margin -612.78%
